Description
Elanco Animal Health’s Hidden Catalyst: Credelio Quattro, Adtab, And Zenrelia Momentum!
Elanco Animal Health reported its first quarter 2026 results showing solid financial and operational performance marked by a 10% organic constant currency revenue growth, exceeding the top end of company guidance. This growth was broad-based, supported by both volume and price increases, and spanned all major geographies and species, underscoring the company’s diversified portfolio strength. The pet health segment, particularly in the U.S., grew 6% despite a weather-related slowdown in the early quarter, with strong rebound momentum in March and April driven by innovation products such as Zenrelia and Credelio Quattro. International pet health similarly achieved 9% organic growth, while the U.S. and international farm animal businesses delivered 15% and 13% growth, respectively. Innovation remained a key growth driver, contributing $287 million in revenue for Q1 and leading Elanco to raise its full-year innovation revenue guidance to $1.2 billion.
